Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Colony formation assays and CCK-8 assays were performed to measure the proliferative capacity of pancreatic cancer.
|
31303762 |
2019 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor-associated fibrosis that is so prevalent in the pancreatic cancer microenvironment was significantly decreased with CCK-receptor antagonist therapy because fibroblasts also have CCK receptors.
|
29927319 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of conditioned medium from PaSCs activated with Notch3 siRNA on pancreatic cancer (LTPA) cells was also detected with CCK-8 assays and scratch experiments.
|
29304760 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immune-competent mice bearing syngeneic pancreatic cancer (Panc02 and mT3-2D) that were treated with the combination of CCK receptor antagonists and immune checkpoint blockade antibodies survived significantly longer with smaller tumors.
|
29043413 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We obtained pancreatic tissues from 5 patients undergoing surgery for pancreatic cancer and prepared 80-μm slices; tissues were exposed to supramaximal cholecystokinin octapeptide (CCK-8) or ethanol and a low concentration of CCK-8 and analyzed by immunoblot and immunofluorescence analyses.
|
29360461 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Though, the exact characterization of CCK and Gs receptors subtype (cholecystokinin type A receptor [CCKAR] and cholecystokinin type B receptor/gastrin receptor [CCKBR/GR]) in stomach cancer (SC) and pancreatic cancer (PC) is still controversial and necessities further validation.
|
27072272 |
2016 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer through the CCK-B receptor (CCK-BR).
|
25469546 |
2015 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will summarize what is known regarding CCK, its receptors, and pancreatic cancer, and also what is unknown and requires further investigation to determine which comes first, the chicken or the egg, "CCK or the cancer."
|
24177032 |
2014 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The suppression of the CCK-2/gastrin signaling pathway by treatment with Z-360 could be a useful approach for potentiating prolonged survival of pancreatic cancer patients receiving gemcitabine therapy.
|
21839751 |
2011 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither treatment of pancreatic cancer cells with CCK antibodies nor the down-regulation of CCK mRNA and peptide by shRNAs altered growth in vitro or in vivo.
|
21186400 |
2011 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies demonstrate that gastrin and the CCK-C receptor form an autocrine loop in human pancreatic cancer that plays a role in regulating growth.
|
14749036 |
2004 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies indicate that the CCK-C receptor is functional and plays a crucial role in growth of human pancreatic cancer.
|
15502642 |
2004 |
Malignant neoplasm of pancreas
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of the CCK-C (cancer) receptor in human pancreatic cancer.
|
12429993 |
2002 |
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines.
|
11444473 |
2001 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Localization of CCK receptors to neoplastic cells within resected human tissue specimens would be suggestive of its potential action as an in vivo promoter of human pancreatic cancer.
|
10457335 |
2000 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that both CCK receptor subtypes can mediate growth inhibitory responses in pancreatic cancer cell lines and raise the possibility that CCK exerts a predominant growth inhibitory action on human pancreatic cancer cells.
|
9041258 |
1997 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is suggested that loxiglumide inhibits the in vivo and in vitro growth of human pancreatic cancer, perhaps independently of its action as a CCK antagonist, and this study also suggests that loxiglumide may be a new type of therapeutic agent to be used for the treatment of human pancreatic cancer.
|
8386784 |
1993 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of a synthetic analogue of CCK (Thr4,Nle7CCK-9) on growth of SW-1990 human pancreatic cancer was examined in two experimental models.
|
2226098 |
1990 |